Impact of microRNAs on cardiovascular diseases and aging
- PMID: 39370977
- PMCID: PMC11459564
- DOI: 10.1177/03000605241279190
Impact of microRNAs on cardiovascular diseases and aging
Abstract
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for both men and women among all ethnicities worldwide. Although significant improvements in the management of CVD occurred in the 20th century, non-invasive, universal, early diagnostic biomarkers and newer therapeutic drugs are needed for clinical treatment by physicians. MicroRNAs (miRNAs) are a class of endogenous, non-coding, single-stranded, small RNA molecules that are critically controlled by all human biological processes. Moreover, dysregulated miRNA expression is directly involved in various CVDs, including stable coronary artery disease and acute coronary syndrome. Several miRNAs that are enriched in the plasma of CVD patients have potential as clinical biomarkers, and overexpression or inhibition of specific miRNAs has novel therapeutic significance in the management of CVD. Aging is a multifactorial physiological process that gradually deteriorates tissue and organ function and is considered a non-modifiable major risk factor for CVDs. Recently, several studies established that various miRNAs essentially regulate aging and aging-related disease processes. This narrative review briefly discusses the recently updated molecular involvement of miRNAs in CVDs, their possible diagnostic, prognostic, and therapeutic value, and their relationship to the aging process.
Keywords: Cardiovascular disease; aging; diagnosis; microRNA; prognosis; therapeutic.
Conflict of interest statement
Declaration of conflicting interestThe authors declare that there is no conflict of interest.
Similar articles
-
miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges.Acta Pharmacol Sin. 2018 Jul;39(7):1073-1084. doi: 10.1038/aps.2018.30. Epub 2018 Jun 7. Acta Pharmacol Sin. 2018. PMID: 29877320 Free PMC article. Review.
-
MicroRNA and Cardiovascular Diseases.Balkan Med J. 2020 Feb 28;37(2):60-71. doi: 10.4274/balkanmedj.galenos.2020.2020.1.94. Epub 2020 Feb 5. Balkan Med J. 2020. PMID: 32018347 Free PMC article.
-
Small Molecules with Big Impacts on Cardiovascular Diseases.Biochem Genet. 2020 Jun;58(3):359-383. doi: 10.1007/s10528-020-09948-z. Epub 2020 Jan 29. Biochem Genet. 2020. PMID: 31997044 Review.
-
MicroRNAs as Potential Biomarkers in Coronary Artery Disease.Curr Top Med Chem. 2023;23(6):454-469. doi: 10.2174/1568026623666221221124530. Curr Top Med Chem. 2023. PMID: 36545717 Review.
-
microRNAs in cardiovascular disease - clinical application.Clin Chem Lab Med. 2017 May 1;55(5):687-704. doi: 10.1515/cclm-2016-0576. Clin Chem Lab Med. 2017. PMID: 27914211 Review.
Cited by
-
Takeda G protein-coupled receptor 5 (TGR5): an attractive therapeutic target for aging-related cardiovascular diseases.Front Pharmacol. 2025 Mar 20;16:1493662. doi: 10.3389/fphar.2025.1493662. eCollection 2025. Front Pharmacol. 2025. PMID: 40183075 Free PMC article. Review.
-
MicroRNA‑21: A potential therapeutic target in lung cancer (Review).Int J Oncol. 2025 Aug;67(2):67. doi: 10.3892/ijo.2025.5773. Epub 2025 Jul 11. Int J Oncol. 2025. PMID: 40641110 Free PMC article. Review.
References
-
- Martin SS, Aday AW, Almarzooq ZI, et al.. Heart Disease and Stroke Statistics-2024 Update: a report from the American Heart Association. Circulation 2024; 149: e347–e913. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical